



Synthesis and Biological Activity of Novel Thyroid Hormone Analogues: 5'-Aryl Substituted GC-1 Derivatives

Grazia Chiellini,^a Ngoc-Ha Nguyen,^a James W. Apriletti,^b John D. Baxter^b
and Thomas S. Scanlan^{a,*}

^a*Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California, San Francisco, CA 94143-0446, USA*

^b*Metabolic Research Unit, University of California, San Francisco, CA 94143-0540, USA*

Received 20 June 2001; accepted 1 August 2001

Abstract—Compounds that selectively modulate thyroid hormone action by functioning as isoform-selective agonists or antagonists of the thyroid hormone receptors (TRs) might be useful for medical therapy. We have synthesized a high affinity TR β -selective agonist ligand, **GC-1**,¹ and optimized the synthetic route to provide large quantities of the compound for animal testing.² In addition to an improvement in efficiency, the new synthetic route offers a chemical handle for selective modification of the thyronine skeleton to produce new derivatives. To explore the effect of **GC-1** core structure modifications on binding to TR isoforms and activation of transcription, we developed here an efficient and flexible route to a new series of 5'-substituted **GC-1** analogues. This route relies on ortho lithiation and in situ boration of the biarylmethane compound **1**, a key intermediate of the revised **GC-1** synthesis,² followed by Suzuki cross-coupling. Using this approach we prepared and tested eleven 5'-substituted **GC-1** analogues. Substitution at the 5'-position decreased binding affinity, but retained TR β -selectivity for most of the compounds. Transactivation assays reveal that most of these compounds function as thyroid hormone agonists, but one compound (**GC-14**) antagonizes the response to thyroid hormone. © 2001 Elsevier Science Ltd. All rights reserved.

Introduction

Thyroid hormone, (T₃, Fig. 1), produced by deiodination of thyroxine (T₄, Fig. 1) in peripheral tissues and by the thyroid gland, exerts critical influences on the growth, development and metabolism of vertebrates.³ Lack of T₃ in early human development results in growth disturbances and severe mental retardation;⁴ later in life, T₃ plays an important role in metabolic balance.⁵ In excess, thyroid hormones may cause weight loss, lowering of plasma lipid levels, tachycardia, atrial arrhythmias, and heart failure.

Essentially all known physiological actions of thyroid hormone are believed to occur through thyroid hormone receptors (TRs), which are members of the nuclear hormone receptor superfamily. Members of this superfamily are ligand-activated transcription regulators that control transcription of hormone-respon-

sive genes.^{6–8} Liganded and unliganded TRs bind at specific *cis*-acting thyroid hormone response elements (TREs), and may bind as monomers, homodimers, or heterodimers with other transcription factors such as the retinoid X receptor (RXR).⁹ Like other nuclear receptors, the TRs have three structural domains; an N-terminal domain, a central DNA binding domain (DBD), and a C-terminal ligand binding domain (LBD). Crystal structures of the ligand-bound TR LBDs have been solved recently and reveal an internal binding mode for the ligand.^{10–12}

There are two TR genes designated TR α and TR β , located on different chromosomes (17 and 3, respectively, in humans). Alternative splicing from each gene generates at least four isoforms: TR α_1 , TR α_2 , TR β_1 and TR β_2 .⁹ The TR α_1 , TR α_2 , and TR β_1 isoforms are widely expressed with characteristic tissue distribution,^{13–15} whereas TR β_2 expression is largely confined to the anterior pituitary.¹⁶ Although thyroid hormone displays no selectivity in binding or activation of the TR isoforms, synthetic analogues have been developed that are TR β -selective agonists.¹⁷ The further development of

*Corresponding author. Tel.: +1-415-476-3620; fax: +1-415-502-7220; e-mail: scanlan@cgl.ucsf.edu




Figure 1.

TR isoform-selective agonists and antagonists will provide useful pharmacological probes for studying thyroid hormone action, and may also provide new therapeutics for the treatment of metabolic disorders.

Compared to steroid ligands for nuclear receptors, T₃ analogue chemistry is relatively unexplored. Previous studies have focused on structure–activity relationships of the features of T₃,¹⁸ as well as development of liver-specific thyroid hormone agonists for treatment of hypercholesterolemia.^{19,20} There are, however, structural features of T₃ that present significant challenges to chemical synthesis, and thus limit analogue design. We initially designed and synthesized the high-affinity TR β -selective thyroid hormone analogue, **GC-1** (Fig. 1), in an attempt to find a thyroid hormone scaffold that was more synthetically accessible than T₃.¹ **GC-1** differs from T₃ in three key respects: replacement of the ether bridge joining the two rings with methylene; replacement of the 3, 5, and 3' iodine atoms with methyl (3,5) and isopropyl (3'); and replacement of 1-amino-propionic acid with oxyacetic acid. These changes produce an analogue with comparable dimensions to T₃ but significantly lower molecular weight.

Because the **GC-1** synthesis is well suited to generating analogues, we are using the scaffold to test the effects of substitution at various positions on the scaffold. We describe here the design and synthesis of a variety of 5'-aryl substituted **GC-1** derivatives (Fig. 1), and the

receptor-binding and transactivation properties of these compounds. These analogues all bind TRs and most retain agonist activity with TR β selectivity. However, one compound (**GC-14**) was found to have TR β -selective antagonist activity.

Results and Discussion

Rationale and design

Our interest in probing the substituent effects at the 5' position of **GC-1** was based on a crystallographic analyses that suggested this would be a good position to introduce a large extension that would result in a ligand with T₃ antagonist activity.²¹ Our recently solved structure of the TR β LBD bound to **GC-1**¹² reveals that the 5' position of the ligand is adjacent to the loop between helices 11 and 12, and substituents at this position would not be accommodated by the ligand binding cavity. In analogy to the raloxifene and tamoxifen-bound estrogen receptor structures,^{22,23} a large substituent at this position may perturb the packing of helix 12 and formation of the coactivator binding surface, resulting in abolishment of transcriptional activity from the liganded TR.

We have recently optimized our original synthesis of **GC-1** using methoxymethyl (MOM) and triisopropylsilyl (TiPS) substituents as phenolic protecting groups.²

The new route allowed us to prepare multigram quantities of **GC-1** and offered a chemical handle for selective modification of the thyronine skeleton to produce new derivatives. Thus, this synthetic route was adopted for the synthesis of a new series of 5'-aryl **GC-1** analogues, and the chemistry used is outlined in Scheme 1.


Chemical synthesis

Compounds **GC-13**, **GC-14**, **GC-19**, **GC-20**, **GC-21**, and **GC-22** were prepared as described in Scheme 1. *Ortho* metalation and in situ boration²⁴ of the biarylmethane compound **1**, which was a key intermediate in the revised synthesis of **GC-1**,² using *n*-butyllithium as the base and triisopropylborate as the electrophile, in a 2:1 THF/hexanes solvent mixture, generates the boronic acid **2**. Suzuki coupling of **2** with a variety of aryl halides produced a series of 5'-aryl analogues **3a–3f**. The lithiation directed by the MOM group turned out to be a difficult step; the rate of lithiation was affected greatly by the polarity of the solvent. The best conditions we found were using a 2:1 THF/hexanes as the reaction solvent. Under these conditions the lithiation and subsequent boration proceeded in good overall yield. The subsequent Suzuki cross-coupling reaction with a



variety of aryl iodides was straightforward and provided the desired cross-coupled products in good yield.

De-silylation of **3a–3f** with tetrabutylammonium fluoride generated the phenols **4a–4f**, which were then mono-alkylated using bromoethylacetate to give the mono-ester **5a–5f**. The desired 5'-aryl substituted thyronine analogues, **GC-13**, **GC-14**, **GC-19**, **GC-20**, **GC-21** and **GC-22** were obtained from the corresponding ester by removal of the methoxymethyl phenolic protecting group under acidic conditions, followed by basic saponification of the ethyl esters.

The 4'-carboxymethyl-amino analogue, **GC-15** and the urea analogue **GC-16** were prepared from the intermediate compound **3b** as shown in Scheme 2. The nitro group reduction of **3b** by iron/acetic acid led to the aniline **6**. Selective removal of the triisopropylsilyl phenolic protecting group of **6** followed by alkylation generated the bis-ester **7**, which after removal of the methoxymethyl phenolic protecting group was subjected to alkaline hydrolysis to yield **GC-15**. Reaction of **6** with phenylisocyanate generated the phenyl urea derivative **8**, which was elaborated to **GC-16** as described above.



Scheme 1. Synthetic route used for the preparation of 5'-aryl substituted **GC-1** analogues: **GC-13**, **GC-14**, **GC-19**, **GC-20**, **GC-21** and **GC-22**.

Scheme 2. Synthesis of **GC-15** and **GC-16**.Scheme 3. Synthesis of **GC-17** and **GC-18**.

Analogues **GC-17** and **GC-18** were prepared as outlined in Scheme 3. *N*-alkylation of **6** with 1-bromo-2-butyne afforded the acetylene derivative **9**, which was elaborated to the final compound **GC-17** as described above. Nitro group reduction of **5b** gave aniline **10**, which was elaborated to **GC-18** as described above.


The guanidine derivative **GC-23** was prepared as outlined in Scheme 4. Guanylation of **6** with Pmc-S-methylisothiourea in the presence of triethylamine and $\text{Hg}(\text{ClO}_4)_2$ in refluxing THF led to the corresponding Pmc-protected guanidine **11**.²⁵ De-silylation of **11** followed by alkylation with *tert*-butylchloroacetate gave compound **12**, which upon acidic hydrolysis provided **GC-23**.

Receptor binding and transactivation properties

The human $\text{TR}\alpha$ and $\text{TR}\beta$ binding affinities for the 5'-aryl substituted **GC-1** analogues **GC-13–GC-23** are shown in Table 1. As a comparison, the parent compound **GC-1** was also tested. Binding affinity was measured with an *in vitro* radioligand-displacement assay, where recombinant human $\text{TR}\alpha_1$ and $\text{TR}\beta_1$ were analyzed independently using a fixed concentration of [^{125}I] T_3 in the presence of a range of concentrations of each analogue. In general, substitution at the 5'-position results in a decreased binding affinity for both $\text{TR}\alpha$ and $\text{TR}\beta$ compared to the parent compound **GC-1**. The parent compound has a K_D of 0.10 nM for $\text{TR}\beta$ whereas all of the 5'-substituted compounds bind $\text{TR}\beta$

with at least a two orders of magnitude reduced affinity. Although binding is impaired, the $\text{TR}\beta$ selectivity of **GC-1** is retained by most of the 5'-substituted compounds. This result is consistent with structural data,¹² which suggests the molecular determinant of selectivity is located on the oxyacetic acid side chain at the opposite end of the thyronine core structure.

To examine the transcriptional transactivation properties of the compounds, HeLa cells were co-transfected with an expression plasmid for $\text{TR}\beta_1$ or $\text{TR}\alpha_1$, together with a TRE-driven luciferase reporter plasmid, and luciferase expression was determined at different concentrations of added ligand. All of the compounds tested, except **GC-14**, were found to be full or nearly full agonists of $\text{TR}\beta_1$ activation and the EC_{50} values for each compound are shown in Table 1. Two of the compounds that had reasonably high affinity for $\text{TR}\alpha_1$ (**GC-13**, **GC-17**) were found to be full agonists of $\text{TR}\alpha_1$, but retained activation selectivity for $\text{TR}\beta_1$ (Table 1). The majority of the compounds were not tested in the $\text{TR}\alpha_1$ activation assay because their relatively poor affinity and potency for $\text{TR}\alpha_1$ made it difficult to obtain complete dose-response curves. The compound **GC-14** displayed weak partial agonism of reporter activation with both $\text{TR}\beta_1$ and $\text{TR}\alpha_1$; the maximum activation by **GC-14** was approximately 20 and 35% compared to **GC-1** for $\text{TR}\beta_1$ and $\text{TR}\alpha_1$, respectively (Table 1). We next tested whether **GC-14** could competitively block $\text{TR}\beta_1$ activation by T_3 in a dose-dependent manner and found that **GC-14** did indeed antagonize the activation of 1 nM











Scheme 4. Synthesis of **GC-23**.

T₃ down to the maximum level of activation observed with **GC-14** alone (Table 1 and Fig. 2). Under these conditions, the IC₅₀ value of this antagonism by **GC-14** was 700 nM (Table 1). A similar competition experiment was performed with **GC-14** and TRα₁, and the IC₅₀ value of T₃ antagonism was 5000 nM (Table 1), further demonstrating the TRβ selectivity of the compound.

The structure–activity relationship (SAR) data provided in Table 1 suggests that the partial agonism/antagonism

of **GC-14** is not related to the size of the para-substituent appended to the 5-phenyl. For example, **GC-16** and **GC-17** bear significantly larger phenyl substituents than the nitro of **GC-14** and they are both agonists with tighter binding affinity to TRβ than **GC-14**. Moreover, the data indicate that the para position of the nitro group in **GC-14** is critical; the meta and ortho analogues (**GC-19** and **GC-20**) are agonists and the ortho analogue **GC-20** is one of the more potent agonists within this series. The data further indicate that for this series of

Table 1. 5'-Aryl substituted GC-1 analogues TRβ₁ and TRα₁ binding affinities and transcriptional activity

	R	KD±SE (nM) ^a		% TRβ ₁ activation ^b	TRβ ₁ EC ₅₀ (IC ₅₀) ^d (nM)	% TRα ₁ activation ^f	TRα ₁ EC ₅₀ (IC ₅₀) (nM)
		hTRβ ₁	hTRα ₁				
GC-1	H	0.1±0.02	1.8±0.2	100	7	100	45
GC-13		30±13	170±10	99	240	99	900
GC-14		35±12	200±60	18	680 ^e	35	5000 ^e
GC-15		23±3	140±15	72	750	n.d.	n.d.
GC-16		45±20	140±15	86	900	n.d.	n.d.
GC-17		12±8	42±8	79	650	100	4000
GC-18		21±5	150±80	100	550	n.d.	n.d.
GC-19		230±30	680±380	100	1120	n.d.	n.d.
GC-20		22±10	170±120	100	660	n.d.	n.d.
GC-21		16±2	120±10	100	630	n.d.	n.d.
GC-22		38±6	200±10	43 ^c	550	n.d.	n.d.
GC-23		320±20	2300±300	57 ^c	4950	n.d.	n.d.

^aThe K_D and standard error (SE) values were calculated by fitting the competition data to the equations of Swillens²⁷ and using the Graph-Pad Prism computer program.

^bHeLa cells were co-transfected with a TRβ₁ expression vector and a TRE-luciferase reporter plasmid. Luciferase activity is expressed as a percent of the TRβ₁ response with 10⁻⁹ M T₃.

^cCompound **GC-22** and **GC-23** tested in competition experiments with T₃ (10⁻⁹M) were not able to antagonize T₃ activation in a dose-dependent manner.

^dThe EC₅₀ value is the concentration of ligand required for half-maximum activation, whereas the IC₅₀ value is the concentration of ligand required for half-maximum inhibition. EC₅₀ values of transcriptional activation were determined graphically from dose response curves. IC₅₀ values were determined graphically from dose-response curves obtained in competition experiments. In these experiments a fixed concentration of T₃ (10⁻⁹ M) was added to the cells along with a range of concentrations of the selected compound. See experimental for more details.

^eThese are IC₅₀ values on TRβ₁ and TRα₁ respectively.

^fHeLa cells were co-transfected with a TRα₁ expression vector and a TRE-luciferase reporter plasmid. Luciferase activity is expressed as a percent of the TRα₁ response with 10⁻⁹ M T₃.




Figure 2. Transcription activation profile for **GC-14** with TR β . Human uterine cervix cancer (HeLa) cells were transfected with 0.5 μ g of the TR β expression vector and 10 μ g of the DR4-Luciferase reporter gene and were treated with indicated concentrations of **GC-14** alone (triangle) or **GC-14** in the presence of 10⁻⁹ M T₃ (circle) for 24 h. Values are the mean $\pm$ SD for three separate experiments, and are expressed as a percent of the TR β response with 10⁻⁹ M T₃, which is set at 100%.

compounds, the electronic properties of the **GC-14** nitro group are also critical as the isosteric carboxylate (**GC-21**), carboxamide (**GC-22**), and guanidinium (**GC-23**) analogues all function as agonists. The SAR data presently in hand suggest a very restrictive set of structural criteria for antagonism within this series mandating an absolute requirement for a nitro group in a particular position on the 5'-phenyl ring.

Conclusions

We have prepared a new series of 5'-substituted thyroid hormone analogues using the TR β -selective thyromimetic **GC-1** as the core element. These compounds were designed to not completely fit into the ligand binding cavity of the TR, and therefore to perturb potentially agonist-induced structure of the TR. All of the compounds within the series show reduced binding affinity for TRs compared to **GC-1**, yet like **GC-1**, they bind TR β in preference to TR α . Surprisingly, all of the compounds in the series function as T₃ agonists in a TRE-driven reporter gene assay with the exception of one compound, **GC-14**. **GC-14** shows weak partial agonist activity by itself, and in competition experiments with T₃, it is able to antagonize T₃ activation of TR α and TR β in a dose-dependent manner. **GC-14** antagonizes the T₃ response more potently with TR β than with TR α indicating that the TR β selectivity of the parent compound **GC-1** is retained in **GC-14**. The available SAR data indicates that the antagonistic property of **GC-14** is dictated by the nitro group attached to the 5'-phenyl extension, and that the size, position, and electronic properties of this nitro group are all essential for the observed activity.

Experimental

General

Proton and carbon-13 nuclear magnetic resonance spectra (¹H NMR and ¹³C NMR) were recorded on either General Electric QE 300 (300 MHz) or Varian Unity 400 MHz spectrometers, using CDCl₃ or MeOD as solvent. Chemical shifts were reported as parts per million downfield from an internal tetramethylsilane standard (δ =0.0 for ¹H) or from solvent references. NMR coupling constants are reported in Hertz. ¹³C NMR were determined using ¹³C pulse sequence parameters. High-resolution mass spectrometry was performed by the National Bio-Organic, Biomedical Mass Spectrometry Resource at UCSF. Flash chromatography on crude products was performed using 230–400 mesh silica gel (Aldrich Chemical Co.). Purity of compounds was determined by TLC using commercial silica gel plates (Alltech, AlugramR Sil G/UV 254) and by ¹H NMR and HRMS.

Glassware was oven- or flame-dried prior to use. Methylene Chloride (anhydrous), tetrahydrofuran (anhydrous) and reagents were purchased from Aldrich Chemical Co. and used without further purification. Reactions were performed under Argon inert atmosphere.

Thyroid hormone receptor ligand binding assays

Full-length hTR α and hTR β were produced using the TNT coupled reticulocyte lysate system (Promega). The ligand binding domains of hTR α and hTR β were expressed in *Escherichia coli* and purified to greater than 95% homogeneity as described previously.²⁶ Competition ligand binding affinities were determined using 1nM [¹²⁵I]T₃ in gel filtration binding assays as described.²⁶ The K_D and standard error (SE) values were calculated by fitting the competition data to the equations of Swillens²⁷ and using the Graph-Pad Prism computer program (GraphPad Software, Inc.).

Transcriptional activation assay

Human uterine cervix cancer (HeLa) cells were maintained in culture and transfected as described previously.^{28,29} Briefly, cells were collected and resuspended in Dulbecco's PBS (0.5 mL/transfection) containing 0.1% dextrose, 10 mg/mL bioprene, and mixed with 0.5 μ g of the appropriate TR expression vector and 10 μ g of the reporter plasmid. The TR expression vector contained either the full length human TR β or human TR α under the control of the cytomegalovirus promoter, CMVTR β and CMVTR α , respectively. The reporter plasmid contained a synthetic TR response element (DR-4) containing two copies of a direct repeat spaced by four nucleotides (AGGTCA-cagg-AGGTCA) cloned immediately upstream of a minimal (−32/+45) thymidine kinase (tk) promoter linked to luciferase coding sequence. Cells (0.8 $\times$ 10⁷) were electroporated using a Bio-Rad gene pulser at 350V and 960 microfarads, pooled in growth medium (DME H-21 with 10% charcoal-treated, hormone stripped, newborn bovine serum), and plated in 6-well dishes. Compounds

were added to the cell culture media as ethanol solutions so as to yield a final ethanol concentration of 0.1%. After incubation for 24 h at 37 °C cells were detached with 1 mL of calcium-magnesium-free PBS, 1 mM EDTA, pre-warmed at 37 °C, and transferred to 1.5 mL Eppendorf tubes. Cells were pelleted by centrifugation in a microfuge for 1 min at room temperature. The supernatants were aspirated and the pellets were lysed by addition of 120 μ L of Tris-Cl 0.25 M pH 7.6, 0.1% Triton. After resuspension by vortexing for 5–10 s, the lysates were pelleted by centrifugation in a microfuge for 5 min at rt. Cellular lysates (100 μ L) were then assayed for luciferase activity as previously described.³⁰

Chemistry

{5'-[2,6-Dimethyl-4-(triisopropyl-silanyloxy)-benzyl]-3-isopropyl-2-methoxymethoxy-phenyl}-boronic acid (2). A solution of **1** (0.5 g, 1.06 mmol) in 5 mL of a 2:1 mixture of dry tetrahydrofuran/hexanes was treated under an inert atmosphere with 2.0 equiv of *n*-butyllithium in hexane and the mixture was stirred 2 h at rt to give a cloudy white suspension. Triisopropyl borate (0.3 mL, 1.2 mmol) was added and the mixture was stirred 1 h at room temperature. The reaction mixture was quenched by pouring into 1 N HCl aq, extracted with ethyl acetate, dried and filtered. The crude boronic acid **2** was used in subsequent Suzuki coupling reactions without further purification.

General procedure for Suzuki coupling of aryl iodines (3a–f)

A stirred mixture of the appropriate aryl iodine (1.0 mmol), Pd₂(dba)₃.CHCl₃ (34.7 mg, 0.03 mmol) in toluene (25 mL) under argon was successively treated with the phenyl boronic acid **2** (565.0 mg, 1.1 mmol), dissolved in a minimum volume of EtOH, and 2 M Cs₂CO₃ (1.1 mL). The resulting mixture was heated at reflux for 8 h, cooled, subjected to filtration. The filtrate was evaporated to dryness in vacuo and the residue was treated with satd NaCl solution. The resulting mixture was extracted with CH₂Cl₂, dried (MgSO₄), filtered, and concentrated in vacuo. The crude material was purified by flash column chromatography on silica gel.

Triisopropyl-[4-(5-isopropyl-6-methoxymethoxy-biphenyl-3ylmethyl)-3,5-dimethyl-phenoxy]-silane (3a). The coupling of iodobenzene with phenylboronic acid was effected using the general procedure to afford 382 mg (70%) of the title compound as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 1.1 (d, 18H, *J*=6.9 Hz), 1.16 (d, 6H, *J*=6.9 Hz), 1.23 (m, 3H), 2.20 (s, 6H), 3.24 (s, 3H), 3.39 (heptet, 1H, *J*=6.9 Hz), 3.95 (s, 2H), 4.49 (s, 2H), 6.59 (s, 2H), 6.78 (s, 1H), 6.99 (s, 1H), 7.22 (m, 1H), 7.32 (m, 2H), 7.48 (d, 2H); ¹³C NMR (300 MHz, CDCl₃) δ 156.2, 152.6, 138.4, 137.3, 136.6, 135.5, 135.3, 129.0, 127.4, 126.1, 125.5, 122.4, 118.3, 101.3, 50.2, 28.9, 24.7, 22.4, 15.3, 14.8, 12.2.

Triisopropyl-[4-(5-isopropyl-6-methoxymethoxy-4-nitro-biphenyl-3ylmethyl)-3,5-dimethyl-phenoxy]-silane (3b). The coupling of 4-iodonitrobenzene with phenylboronic acid

was effected using the general procedure to afford 370 mg (68%) of the title compound as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 1.1 (d, 18H, *J*=6.9 Hz), 1.16 (d, 6H, *J*=6.9 Hz), 1.23 (m, 3H), 2.20 (s, 6H), 3.18 (s, 3H), 3.37 (heptet, 1H, *J*=6.9 Hz), 3.96 (s, 2H), 4.52 (s, 2H), 6.61 (s, 2H), 6.71 (s, 1H), 6.98 (s, 1H), 7.63 (d, 2H, *J*=8.7 Hz), 8.22 (d, 2H, *J*=8.7 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 156.2, 152.6, 147.3, 142.7, 138.4, 137.3, 135.5, 135.3, 128.3, 126.1, 125.5, 124.1, 122.4, 118.3, 101.3, 50.2, 28.9, 24.7, 22.4, 15.3, 14.8, 12.1.

Triisopropyl-[4-(5-isopropyl-6-methoxymethoxy-3'-nitro-biphenyl-3ylmethyl)-3,5-dimethyl-phenoxy]-silane (3c). The coupling of 3-iodonitrobenzene with phenylboronic acid was effected using the general procedure to afford 380 mg (65%) of the title compound as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 1.1 (d, 18H, *J*=6.9 Hz), 1.18 (d, 6H, *J*=6.9 Hz), 1.24 (m, 3H), 2.19 (s, 6H), 3.18 (s, 3H), 3.36 (heptet, 1H, *J*=6.9 Hz), 3.97 (s, 2H), 4.53 (s, 2H), 6.61 (s, 2H), 6.74 (s, 1H), 6.94 (s, 1H), 7.52 (t, 1H, *J*=8.0 Hz), 7.77 (d, 1H, *J*=8.0 Hz), 8.15 (d, 1H, *J*=8.0), 8.37 (s, 1H); ¹³C NMR (300 MHz, CDCl₃) δ 156.2, 152.6, 148.9, 138.4, 137.5, 137.3, 135.5, 135.3, 133.5, 129.9, 126.1, 125.5, 122.5, 122.4, 118.3, 101.3, 50.2, 28.9, 24.7, 22.4, 15.3, 14.8, 12.2.

Triisopropyl-[4-(5-isopropyl-6-methoxymethoxy-2'-nitro-biphenyl-3ylmethyl)-3,5-dimethyl-phenoxy]-silane (3d). The coupling of 2-iodonitrobenzene with phenylboronic acid was effected using the general procedure to afford 435 mg (75%) of the title compound as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 1.1 (d, 18H, *J*=6.9 Hz), 1.16 (d, 6H, *J*=6.9 Hz), 1.23 (m, 3H), 2.18 (s, 6H), 3.08 (s, 3H), 3.27 (heptet, 1H, *J*=6.9 Hz), 3.95 (s, 2H), 4.51 (s, 2H), 6.60 (s, 2H), 6.63 (s, 1H), 6.97 (s, 1H), 7.40 (d, 1H, *J*=7.6 Hz), 7.43 (m, 1H), 7.56 (m, 1H), 7.90 (d, 1H, *J*=8.0); ¹³C NMR (300 MHz, CDCl₃) δ 156.2, 152.6, 147.3, 138.4, 137.3, 135.5, 135.3, 135.1, 131.7, 128.3, 126.1, 124.1, 122.4, 118.3, 101.3, 50.2, 28.9, 24.7, 22.4, 15.3, 14.8, 12.2.

5'-[2,6-Dimethyl-4-(triisopropyl-silanyloxy)-benzyl]-3'-isopropyl-2'-methoxymethoxy-biphenyl-4-carboxylic acid (3e). The coupling of 4-iodobenzoic acid with phenylboronic acid was effected using the general procedure to afford 390 mg (71%) of the title compound as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 1.1 (d, 18H, *J*=6.9 Hz), 1.16 (d, 6H, *J*=6.9 Hz), 1.23 (m, 3H), 2.21 (s, 6H), 3.19 (s, 3H), 3.39 (heptet, 1H, *J*=6.9 Hz), 3.97 (s, 2H), 4.53 (s, 2H), 6.61 (s, 2H), 6.76 (s, 1H), 6.94 (s, 1H), 7.60 (d, 2H, *J*=8.0 Hz), 8.12 (d, 2H, *J*=8.0 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 172.0, 156.2, 152.6, 141.8, 138.4, 137.3, 135.5, 135.3, 130.6, 129.5, 127.3, 126.1, 122.4, 118.3, 101.3, 50.2, 28.9, 24.7, 22.4, 15.3, 14.8, 12.0.

5'-(2,6-Dimethyl-4-(triisopropyl-silanyloxy)-benzyl)-3'-isopropyl-2'-methoxymethoxy-biphenyl-4-carboxylic acid amide (3f). The coupling of 4-bromobenzamide with the phenyl boronic acid **6** was effected using the general procedure with 3.0 mol% Pd₂(dba)₃.CHCl₃ and 2 M Cs₂CO₃ to afford 200 mg (70%) of the title compound as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 1.1 (d,

18H, $J=6.9$ Hz), 1.18 (d, 6H, $J=6.9$ Hz), 1.25 (m, 3H), 2.18 (s, 6H), 3.20 (s, 3H), 3.39 (heptet, 1H, $J=6.9$ Hz), 3.95 (s, 2H), 4.50 (s, 2H), 6.60 (s, 2H), 6.74 (s, 1H), 6.92 (s, 1H), 7.55 (d, 2H, $J=8.0$ Hz), 7.81 (d, 2H, $J=8.0$ Hz); ^{13}C NMR (300 MHz, CDCl_3) δ 169.7, 156.2, 152.6, 140.8, 138.4, 137.3, 135.5, 135.3, 132.6, 127.8, 127.5, 126.1, 122.4, 118.3, 101.3, 50.2, 28.9, 24.7, 22.4, 15.3, 14.8, 12.2.

4-[5-Isopropyl-6-methoxymethoxy-biphenyl-3-ylmethyl)-3,5-dimethyl-phenol (4a). Compound **3a** (137 mg, 0.25 mmol) and Bu_4NF (0.315 mL, 1.0 M in THF) were combined in a round bottom flask. Deprotection was determined to be nearly instantaneous by TLC. The reaction mixture was diluted with ethyl acetate (25 mL) and washed with water (2×25 mL) and brine (30 mL), dried, and concentrated. The crude product was purified by flash column chromatography (80:20 hexane/ethyl acetate) to yield **4a** (90.0 mg, 0.24 mmol, 95%) ^1H NMR (300 MHz, CDCl_3) δ 1.20 (d, 6H, $J=6.9$ Hz), 2.20 (s, 6H), 3.25 (s, 3H), 3.44 (heptet, 1H, $J=6.9$ Hz), 3.95 (s, 2H), 4.50 (s, 2H), 6.53 (s, 2H), 6.75 (s, 1H), 6.94 (s, 1H), 7.28 (m, 1H), 7.37 (m, 2H), 7.48 (d, 2H); ^{13}C NMR (300 MHz, CDCl_3) δ 156.2, 154.6, 138.9, 137.0, 136.6, 135.5, 135.3, 129.0, 127.4, 126.1, 125.5, 122.4, 113.9, 101.3, 50.2, 28.9, 24.7, 22.4, 15.3.

4-[5-Isopropyl-6-methoxymethoxy-4'-nitro-biphenyl-3-ylmethyl)-3,5-dimethyl-phenol (4b). Compound **3b** (150 mg, 0.25 mmol) and Bu_4NF (0.315 mL, 1.0 M in THF) were combined in a round bottom flask. Deprotection was determined to be nearly instantaneous by TLC. The reaction mixture was diluted with ethyl acetate (25 mL) and washed with water (2×25 mL) and brine (30 mL), dried, and concentrated. The crude product was purified by flash column chromatography (80:20 hexane/ethyl acetate) to yield **4b** (100.0 mg, 0.23 mmol, 95%) ^1H NMR (300 MHz, CDCl_3) δ 1.21 (d, 6H, $J=6.9$ Hz), 2.20 (s, 6H), 3.19 (s, 3H), 3.37 (heptet, 1H, $J=6.9$ Hz), 3.96 (s, 2H), 4.53 (s, 2H), 6.55 (s, 2H), 6.70 (s, 1H), 7.03 (s, 1H), 7.63 (d, 2H, $J=8.7$ Hz), 8.22 (d, 2H, $J=8.7$ Hz); ^{13}C NMR (300 MHz, CDCl_3) δ 156.2, 154.6, 147.3, 142.7, 138.9, 137.0, 135.5, 135.3, 128.3, 126.1, 125.5, 124.1, 122.4, 113.9, 101.3, 50.2, 28.9, 24.7, 22.4, 15.3.

4-[5-Isopropyl-6-methoxymethoxy-3'-nitro-biphenyl-3-ylmethyl)-3,5-dimethyl-phenol (4c). Compound **3c** (150 mg, 0.25 mmol) and Bu_4NF (0.315 mL, 1.0 M in THF) were combined in a round bottom flask. Deprotection was determined to be nearly instantaneous by TLC. The reaction mixture was diluted with ethyl acetate (25 mL) and washed with water (2×25 mL) and brine (30 mL), dried, and concentrated. The crude product was purified by flash column chromatography (80:20 hexane/ethyl acetate) to yield **4c** (100.0 mg, 0.22 mmol, 90%) ^1H NMR (300 MHz, CDCl_3) δ 1.19 (d, 6H, $J=6.9$ Hz), 2.21 (s, 6H), 3.16 (s, 3H), 3.38 (heptet, 1H, $J=6.9$ Hz), 3.97 (s, 2H), 4.53 (s, 2H), 6.56 (s, 2H), 6.73 (s, 1H), 6.99 (s, 1H), 7.54 (t, 1H, $J=8.0$ Hz), 7.78 (d, 1H, $J=7.6$ Hz), 8.15 (d, 1H, $J=8.0$), 8.36 (s, 1H); ^{13}C NMR (300 MHz, CDCl_3) δ 156.2, 154.6, 148.9, 138.9, 137.5, 137.0, 135.5, 135.3, 133.5, 129.9, 126.1, 125.5, 122.5, 122.4, 113.9, 101.3, 50.2, 28.9, 24.7, 22.4, 15.3.

4-[5-Isopropyl-6-methoxymethoxy-2'-nitro-biphenyl-3-ylmethyl)-3,5-dimethyl-phenol (4d). Compound **3d** (150 mg, 0.25 mmol) and Bu_4NF (0.315 mL, 1.0 M in THF) were combined in a round bottom flask. Deprotection was determined to be nearly instantaneous by TLC. The reaction mixture was diluted with ethyl acetate (25 mL) and washed with water (2×25 mL) and brine (30 mL), dried, and concentrated. The crude product was purified by flash column chromatography (80:20 hexane/ethyl acetate) to yield **4d** (95.0 mg, 0.20 mmol, 85%) ^1H NMR (300 MHz, CDCl_3) δ 1.18 (d, 6H, $J=6.9$ Hz), 2.20 (s, 6H), 3.11 (s, 3H), 3.32 (heptet, 1H, $J=6.9$ Hz), 3.95 (s, 2H), 4.52 (s, 2H), 6.56 (s, 2H), 6.63 (s, 1H), 6.97 (s, 1H), 7.41 (d, 1H, $J=7.6$ Hz), 7.45 (m, 1H), 7.56 (m, 1H), 7.92 (d, 1H, $J=8.0$); ^{13}C NMR (300 MHz, CDCl_3) δ 156.2, 154.6, 147.3, 138.9, 137.0, 135.5, 135.3, 135.1, 131.7, 128.3, 126.1, 124.1, 122.4, 113.9, 101.3, 50.2, 28.9, 24.7, 22.4, 15.3.

5'-(4-Hydroxy-2,6-dimethyl-benzyl)-3'-isopropyl-2'-methoxymethoxy-biphenyl-4-carboxylic acid (4e). Compound **3e** (148 mg, 0.25 mmol) and Bu_4NF (0.315 mL, 1.0 M in THF) were combined in a round bottom flask. Deprotection was determined to be nearly instantaneous by TLC. The reaction mixture was diluted with ethyl acetate (25 mL) and washed with water (2×25 mL) and brine (30 mL), dried, and concentrated. The crude product was purified by flash column chromatography (80:20 hexane/ethyl acetate) to yield **4e** (96.0 mg, 0.22 mmol, 90%) ^1H NMR (300 MHz, CDCl_3) δ 1.21 (d, 6H, $J=6.9$ Hz), 2.19 (s, 6H), 3.18 (s, 3H), 3.40 (heptet, 1H, $J=6.9$ Hz), 3.95 (s, 2H), 4.51 (s, 2H), 6.56 (s, 2H), 6.71 (s, 1H), 6.99 (s, 1H), 7.54 (d, 2H, $J=8.0$ Hz), 8.09 (d, 2H, $J=8.0$ Hz); ^{13}C NMR (300 MHz, CDCl_3) δ 172.0, 156.2, 154.6, 141.8, 138.9, 137.0, 135.5, 135.3, 130.6, 129.5, 127.3, 126.1, 122.4, 113.9, 101.3, 50.2, 28.9, 24.7, 22.4, 15.3.

5'-(4-Hydroxy-2,6-dimethyl-benzyl)-3'-isopropyl-2'-methoxymethoxy-biphenyl-4-carboxylic acid amide (4f). Compound **3f** (150 mg, 0.25 mmol) and Bu_4NF (0.315 mL, 1.0 M in THF) were combined in a round bottom flask. Deprotection was determined to be nearly instantaneous by TLC. The reaction mixture was diluted with ethyl acetate (25 mL) and washed with water (2×25 mL) and brine (30 mL), dried, and concentrated. The crude product was purified by flash column chromatography (80:20 hexane/ethyl acetate) to yield **4f** (98.0 mg, 0.22 mmol, 90%) ^1H NMR (300 MHz, CDCl_3) δ 1.20 (d, 6H, $J=6.9$ Hz), 2.19 (s, 6H), 3.20 (s, 3H), 3.40 (heptet, 1H, $J=6.9$ Hz), 3.93 (s, 2H), 4.50 (s, 2H), 6.56 (s, 2H), 6.70 (s, 1H), 6.99 (s, 1H), 7.55 (d, 2H, $J=8.0$ Hz), 7.81 (d, 2H, $J=8.0$ Hz); ^{13}C NMR (300 MHz, CDCl_3) δ 169.7, 156.2, 154.6, 140.8, 138.9, 137.0, 135.5, 135.3, 132.6, 127.8, 127.5, 126.1, 122.4, 113.9, 101.3, 50.2, 28.9, 24.7, 22.4, 15.3.

[4-(5-Isopropyl-6-methoxymethoxy-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid ethyl ester (5a). To cesium carbonate (334.0 mg, 1.02 mmol) and **4a** (80.0 mg, 0.20 mmol) in 5 mL of DMF was added ethyl-bromoacetate (0.023 mL, 0.20 mmol). The reaction mixture was stirred for 30 min at room temperature,

poured into 15 mL of cold 1 N HCl, and extracted with ethyl acetate (3 × 10 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 100 mg of crude, which was purified using flash column chromatography (silica gel, 90:10 hexane/ethyl acetate) to yield **5a** (88.0 mg, 0.19 mmol, 90%). ¹H NMR (300 MHz, CDCl₃) δ 1.20 (d, 6H, *J* = 6.9 Hz), 1.29 (t, 3H, *J* = 7.2 Hz), 2.20 (s, 6H), 3.25 (s, 3H), 3.44 (heptet, 1H, *J* = 6.9 Hz), 3.95 (s, 2H), 4.27 (q, 2H, *J* = 7.2 Hz), 4.50 (s, 2H), 4.61 (s, 2H), 6.60 (s, 2H), 6.72 (s, 1H), 6.93 (s, 1H), 7.29 (m, 1H), 7.35 (m, 2H), 7.46 (d, 2H); ¹³C NMR (300 MHz, CDCl₃) δ 159.3.6, 156.2, 138.5, 136.7, 136.6, 135.5, 135.3, 129.0, 127.4, 126.1, 125.5, 122.4, 112.3, 101.3, 75.6, 59.5, 50.2, 28.9, 24.7, 22.4, 15.3, 13.6.

[4-(5-Isopropyl-6-methoxymethoxy-4'-nitro-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid ethyl ester (5b). To cesium carbonate (334.0 mg, 1.02 mmol) and **4b** (90 mg, 0.20 mmol) in 5 mL of DMF was added ethylbromoacetate (0.023 mL, 0.20 mmol). The reaction mixture was stirred for 30 min at rt, poured into 15 mL of cold 1 N HCl, and extracted with ethyl acetate (3 × 10 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 100 mg of crude, which was purified using flash column chromatography (silica gel, 90:10 hexane/ethyl acetate) to yield **5b** (98.0 mg, 0.19 mmol, 90%). ¹H NMR (300 MHz, CDCl₃) δ 1.21 (d, 6H, *J* = 6.9 Hz), 1.29 (t, 3H, *J* = 7.2 Hz), 2.23 (s, 6H), 3.19 (s, 3H), 3.39 (heptet, 1H, *J* = 6.9 Hz), 3.98 (s, 2H), 4.27 (q, 2H, *J* = 7.2 Hz), 4.53 (s, 2H), 4.61 (s, 2H), 6.64 (s, 2H), 6.67 (s, 1H), 7.02 (s, 1H), 7.63 (d, 2H, *J* = 8.7 Hz), 8.23 (d, 2H, *J* = 8.7 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 159.3, 156.2, 147.3, 142.7, 138.5, 136.7, 135.5, 135.3, 128.3, 126.1, 125.5, 124.1, 122.4, 112.3, 101.3, 75.6, 59.5, 50.2, 28.9, 24.7, 22.4, 15.3, 13.6.

5-Isopropyl-6-methoxymethoxy-3'-nitro-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid ethyl ester (5c). To cesium carbonate (334.0 mg, 1.02 mmol) and **4c** (90 mg, 0.20 mmol) in 5 mL of DMF was added ethylbromoacetate (0.023 mL, 0.20 mmol). The reaction mixture was stirred for 30 min at room temperature, poured into 15 mL of cold 1 N HCl, and extracted with ethyl acetate (3 × 10 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 100 mg of crude, which was purified using flash column chromatography (silica gel, 90:10 hexane/ethyl acetate) to yield **5c** (93.0 mg, 0.18 mmol, 85%). ¹H NMR (300 MHz, CDCl₃) δ 1.20 (d, 6H, *J* = 6.9 Hz), 1.29 (t, 3H, *J* = 7.2 Hz), 2.23 (s, 6H), 3.16 (s, 3H), 3.38 (heptet, 1H, *J* = 6.9 Hz), 3.98 (s, 2H), 4.27 (q, 2H, *J* = 7.2 Hz), 4.49 (s, 2H), 4.53 (s, 2H), 6.62 (s, 2H), 6.73 (s, 1H), 6.98 (s, 1H), 7.54 (t, 1H, *J* = 8.0 Hz), 7.78 (d, 1H, *J* = 7.6 Hz), 8.14 (d, 1H, *J* = 8.0 Hz), 8.36 (s, 1H); ¹³C NMR (300 MHz, CDCl₃) δ 159.3, 156.2, 148.9, 138.5, 137.5, 136.7, 135.5, 135.3, 133.5, 129.9, 126.1, 125.5, 122.5, 122.4, 112.3, 101.3, 75.6, 59.5, 50.2, 28.9, 24.7, 22.4, 15.3, 13.6.

5-Isopropyl-6-methoxymethoxy-2'-nitro-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid ethyl ester (5d). To cesium carbonate (334.0 mg, 1.02 mmol) and **4d** (90 mg, 0.20 mmol) in 5 mL of DMF was added ethylbromoacetate (0.023 mL, 0.20 mmol). The reaction

mixture was stirred for 30 min at room temperature, poured into 15 mL of cold 1 N HCl, and extracted with ethyl acetate (3 × 10 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 100 mg of crude, which was purified using flash column chromatography (silica gel, 90:10 hexane/ethyl acetate) to yield **5d** (98.0 mg, 0.19 mmol, 90%). ¹H NMR (300 MHz, CDCl₃) δ 1.18 (d, 6H, *J* = 6.9 Hz), 1.27 (t, 3H, *J* = 7.2 Hz), 2.20 (s, 6H), 3.08 (s, 3H), 3.29 (heptet, 1H, *J* = 6.9 Hz), 3.97 (s, 2H), 4.13 (q, 2H, *J* = 7.2 Hz), 4.52 (s, 2H), 4.59 (s, 2H), 6.57 (s, 2H), 6.60 (s, 1H), 7.01 (s, 1H), 7.41 (d, 1H, *J* = 7.6 Hz), 7.44 (m, 1H), 7.58 (m, 1H), 7.90 (d, 1H, *J* = 8.0); ¹³C NMR (300 MHz, CDCl₃) δ 159.3, 156.2, 147.3, 138.5, 136.7, 135.5, 135.3, 135.1, 128.3, 126.1, 125.5, 122.4, 112.3, 101.3, 75.6, 59.5, 50.2, 28.9, 24.7, 22.4, 15.3, 13.6.

5'-(4-Ethoxycarbonylmethoxy-2,6-dimethyl-benzyl)-3'-isopropyl-2-methoxymethoxy-biphenyl-4-carboxylic acid (5e). To cesium carbonate (334.0 mg, 1.02 mmol) and **4e** (87.0 mg, 0.20 mmol) in 5 mL of DMF was added ethylbromoacetate (0.023 mL, 0.20 mmol). The reaction mixture was stirred for 30 min at rt, poured into 15 mL of cold 1 N HCl, and extracted with ethylacetate (3 × 10 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 100 mg of crude, which was purified using flash column chromatography (silica gel, 90:10 hexane/ethyl acetate) to yield **5e** (95.0 mg, 0.19 mmol, 89%). ¹H NMR (300 MHz, CDCl₃) δ 1.21 (d, 6H, *J* = 6.9 Hz), 1.27 (t, 3H, *J* = 7.2 Hz), 2.22 (s, 6H), 3.19 (s, 3H), 3.40 (heptet, 1H, *J* = 6.9 Hz), 3.96 (s, 2H), 4.26 (q, 2H, *J* = 7.2 Hz), 4.49 (s, 2H), 4.74 (s, 2H), 6.61 (s, 2H), 6.72 (s, 1H), 6.95 (s, 1H), 7.54 (d, 2H, *J* = 8.0 Hz), 8.08 (d, 2H, *J* = 8.0 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 172.0, 171.0, 159.3, 156.2, 141.8, 138.5, 136.7, 135.5, 135.3, 135.3, 129.5, 127.3, 126.1, 122.4, 112.3, 101.3, 75.6, 59.5, 50.2, 28.9, 24.7, 22.4, 15.3, 13.6.

[4-(4'-Carbamoyl-5-isopropyl-6-methoxymethoxy-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid ethyl ester (5f). To cesium carbonate (335.6 mg, 1.03 mmol) and **4f** (90 mg, 0.21 mmol) in 5 mL of DMF was added ethylbromoacetate (0.024 mL, 0.21 mmol). The reaction mixture was stirred for 30 min at room temperature, poured into 15 mL of cold 1 N HCl, and extracted with ethyl acetate (3 × 10 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 110 mg of crude, which was purified using flash column chromatography (silica gel, 90:10 hexane/ethyl acetate) to yield **5f** (95.0 mg, 0.19 mmol, 90%). ¹H NMR (300 MHz, CDCl₃) δ 1.21 (d, 6H, *J* = 6.9 Hz), 1.28 (t, 3H, *J* = 7.2 Hz), 2.22 (s, 6H), 3.19 (s, 3H), 3.40 (heptet, 1H, *J* = 6.9 Hz), 3.97 (s, 2H), 4.25 (q, 2H, *J* = 7.2 Hz), 4.49 (s, 2H), 4.74 (s, 2H), 6.61 (s, 2H), 6.71 (s, 1H), 6.95 (s, 1H), 7.55 (d, 2H, *J* = 8.4 Hz), 7.82 (d, 2H, *J* = 8.4 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 169.7, 171.0, 159.3, 156.2, 140.8, 138.5, 136.7, 135.5, 135.3, 132.6, 127.8, 127.5, 126.1, 122.4, 112.3, 101.3, 75.6, 59.5, 50.2, 28.9, 24.7, 22.4, 15.3, 13.6.

[4-(6-Hydroxy-5-isopropyl-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid (GC-13). To the ester **5a**

(72.0 mg, 0.15 mmol) in 4 mL of a 50% (v/v) mixture of *i*-PrOH and THF was added 0.2 mL of 1 N HCl. The reaction mixture was stirred for 2 h at rt, diluted with 5 mL of water and extracted with ethyl acetate (2×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 60 mg of the corresponding *O*-methoxymethyl deprotected phenol, which was used directly in the following step. To the above phenol (50.0 mg, 0.11 mmol) in 4 mL of methanol was added 2.6 mL of 1 N NaOH. The reaction mixture was stirred for 1 h at rt, acidified with 3 mL of 2 N HCl, and extracted with ethyl acetate (2×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to give **GC-13** (40.0 mg, 0.099 mmol, 78%). ¹H NMR (300 MHz, CD₃OD) δ 1.18 (d, 6H, *J*=6.9 Hz), 2.22 (s, 6H), 3.32 (heptet, 1H, *J*=6.9 Hz), 3.92 (s, 2H), 4.37 (s, 2H), 6.57 (s, 1H), 6.65 (s, 2H), 6.87 (s, 1H), 7.28 (m, 1H), 7.35 (m, 2H), 7.42 (d, 2H); ¹³C NMR (300 MHz, CD₃OD) δ 159.3, 151.5, 138.5, 136.7, 136.6, 135.8, 136.9, 129.0, 127.4, 126.1, 125.5, 122.4, 112.3, 77.8, 28.9, 24.7, 22.1, 15.3. HR-MS calcd for C₂₆H₂₈O₄: 404.1988. Found: 404.2000.

[4-(6-Hydroxy-5-isopropyl-4'-nitro-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid (GC-14). To the ester **5b** (75.0 mg, 0.14 mmol) in 4 mL of a 50% (v/v) mixture of *i*-PrOH and THF was added 0.2 mL of 1 N HCl. The reaction mixture was stirred for 2 h at rt, diluted with 5 mL of water and extracted with ethyl acetate (2×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 65 mg of the corresponding *O*-methoxymethyl deprotected phenol, which was used directly in the following step. To the above phenol (50.0 mg, 0.10 mmol) in 4 mL of methanol was added 2.6 mL of 1 N NaOH. The reaction mixture was stirred for 1 h at rt, acidified with 3 mL of 2 N HCl, and extracted with ethyl acetate (2×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to give **GC-14** (33.0 mg, 0.075 mmol, 75%). ¹H NMR (300 MHz, CD₃OD) δ 1.19 (d, 6H, *J*=6.9 Hz), 2.21 (s, 6H), 3.31 (heptet, 1H, *J*=6.9 Hz), 3.94 (s, 2H), 4.36 (s, 2H), 6.63 (s, 1H), 6.65 (s, 2H), 6.95 (s, 1H), 7.62 (d, 2H, *J*=8.7 Hz), 8.21 (d, 2H, *J*=8.7 Hz); ¹³C NMR (300 MHz, CD₃OD) δ 159.3, 151.5, 147.3, 142.7, 138.5, 136.9, 136.7, 135.8, 128.3, 126.5, 125.9, 124.1, 124.0, 112.3, 77.8, 28.9, 24.7, 22.1, 15.3. HR-MS calcd for C₂₆H₂₇NO₆: 449.1838. Found: 449.1844.

[4-(6-Hydroxy-5-isopropyl-3'-nitro-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid (GC-19). To the ester **5c** (75 mg, 0.14 mmol) in 4 mL of a 50% (v/v) mixture of *i*-PrOH and THF was added 0.2 mL of 1 N HCl. The reaction mixture was stirred for 2 h at rt, diluted with 5 mL of water and extracted with ethyl acetate (2×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 60 mg of the corresponding *O*-methoxymethyl deprotected phenol, which was used directly in the following step. To the above phenol (50.0 mg, 0.10 mmol) in 4 mL of methanol was added 2.6 mL of 1 N NaOH. The reaction mixture was stirred for 1 h at rt, acidified with 3 mL of 2 N HCl, and extracted with ethyl acetate (2×25 mL). The combined

organic portions were dried (MgSO₄) and evaporated to give **GC-19** (36.0 mg, 0.082 mmol, 80%). ¹H NMR (300 MHz, CDCl₃) δ 1.23 (d, 6H, *J*=6.9 Hz), 2.25 (s, 6H), 3.18 (heptet, 1H, *J*=6.9 Hz), 3.96 (s, 2H), 4.65 (s, 2H), 6.62 (s, 1H), 6.65 (s, 2H), 6.95 (s, 1H), 7.59 (t, 1H, *J*=8.0 Hz), 7.74 (d, 1H, *J*=7.6 Hz), 8.19 (d, 1H, *J*=8.0), 8.29 (s, 1H); ¹³C NMR (300 MHz, CDCl₃) δ 159.3, 151.5, 148.9, 138.5, 137.5, 136.9, 136.7, 135.8, 133.5, 129.9, 126.5, 125.9, 122.5, 122.4, 112.3, 77.8, 28.9, 24.7, 22.1, 15.3. HR-MS calcd for C₂₆H₂₇NO₆: 449.1838. Found: 449.1848.

[4-(6-Hydroxy-5-isopropyl-2'-nitro-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid (GC-20). To the ester **5d** (75 mg, 0.14 mmol) in 4 mL of a 50% (v/v) mixture of *i*-PrOH and THF was added 0.2 mL of 1 N HCl. The reaction mixture was stirred for 2 h at rt, diluted with 5 mL of water and extracted with ethyl acetate (2×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 62 mg of the corresponding *O*-methoxymethyl deprotected phenol, which was used directly in the following step. To the above phenol (52.0 mg, 0.104 mmol) in 4 mL of methanol was added 2.6 mL of 1 N NaOH. The reaction mixture was stirred for 1 h at rt, acidified with 3 mL of 2 N HCl, and extracted with ethyl acetate (2×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to give **GC-20** (34.0 mg, 0.077 mmol, 75%). ¹H NMR (300 MHz, CDCl₃) δ 1.19 (d, 6H, *J*=6.9 Hz), 2.23 (s, 6H), 3.11 (heptet, 1H, *J*=6.9 Hz), 3.94 (s, 2H), 4.65 (s, 2H), 6.49 (s, 1H), 6.63 (s, 2H), 6.95 (s, 1H), 7.36 (d, 1H, *J*=7.6 Hz), 7.48 (m, 1H), 7.60 (m, 1H), 7.91 (d, 1H, *J*=8.0); ¹³C NMR (300 MHz, CDCl₃) δ 159.3, 151.5, 147.3, 138.5, 136.9, 136.7, 135.8, 135.1, 131.7, 128.3, 126.5, 125.9, 124.0, 124.1, 112.3, 77.8, 28.9, 24.7, 22.1, 15.3. HR-MS calcd for C₂₆H₂₇NO₆: 449.1838. Found: 449.1839.

5'-(4-Carboxymethoxy-2,6-dimethyl-benzyl)-2'-hydroxy-3'-isopropyl-biphenyl-4-carboxylic acid (GC-21). To the ester **5e** (83.0 mg, 0.16 mmol) in 5 mL of a 50% (v/v) mixture of *i*-PrOH and THF was added 0.3 mL of 1 N HCl. The reaction mixture was stirred for 2 h at rt, diluted with 7 mL of water and extracted with ethyl acetate (3×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 70 mg of the corresponding *O*-methoxymethyl deprotected phenol, which was used directly in the following step. To the above phenol (65.0 mg, 0.14 mmol) in 4 mL of methanol was added 2.6 mL of 1 N NaOH. The reaction mixture was stirred for 1 h at rt, acidified with 3 mL of 2 N HCl, and extracted with ethyl acetate (2×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to give **GC-21** (51.0 mg, 0.11 mmol, 75%). ¹H NMR (300 MHz, CDCl₃) δ 1.21 (d, 6H, *J*=6.9 Hz), 2.23 (s, 6H), 3.20 (heptet, 1H, *J*=6.9 Hz), 3.96 (s, 2H), 4.69 (s, 2H), 6.63 (s, 1H), 6.76 (s, 2H), 6.99 (s, 1H), 7.53 (d, 2H, *J*=8.0 Hz), 8.18 (d, 2H, *J*=8.0 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 176.0, 172.0, 159.3, 151.5, 141.8, 138.5, 136.9, 136.7, 135.8, 130.6, 129.5, 127.3, 126.5, 124.0, 112.3, 77.8, 28.9, 24.7, 22.1, 15.3. HR-MS calcd for C₂₇H₂₈O₆: 448.1885. Found: 448.1889.

[4-(4'-Carbamoyl-6-hydroxy-5-isopropyl-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid (GC-22). To the ester **5f** (80.0 mg, 0.14 mmol) in 4 mL of a 50% (v/v) mixture of *i*-PrOH and THF was added 0.2 mL of 1 N HCl. The reaction mixture was stirred for 2 h at rt, diluted with 5 mL of water and extracted with ethyl acetate (2×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 65 mg of the corresponding *O*-methoxymethyl deprotected phenol, which was used directly in the following step. To the above phenol (53.0 mg, 0.10 mmol) in 4 mL of methanol was added 2.6 mL of 1 N NaOH. The reaction mixture was stirred for 1 h at rt, acidified with 3 mL of 2 N HCl, and extracted with ethyl acetate (2×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to give **GC-22** (34.0 mg, 0.075 mmol, 75%). ¹H NMR (300 MHz, CDCl₃) δ 1.21 (d, 6H, *J*=6.9 Hz), 2.23 (s, 6H), 3.25 (heptet, 1H, *J*=6.9 Hz), 3.94 (s, 2H), 4.35 (s, 2H), 6.60 (s, 1H), 6.65 (s, 2H), 6.90 (s, 1H), 7.49 (d, 2H, *J*=8.4 Hz), 7.88 (d, 2H, *J*=8.0 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 176.0, 169.7, 159.3, 151.5, 140.0, 138.5, 136.9, 136.7, 135.8, 132.6, 127.8, 127.5, 126.5, 124.0, 112.3, 77.8, 28.9, 24.7, 22.1, 15.3. HR-MS calcd for C₂₇H₂₉NO₅: 447.2025. Found: 447.2037.

5'-[2,6-Dimethyl-4-(triisopropyl-silanyloxy)-benzyl]-3'-isopropyl-2'-methoxymethoxy-biphenyl-4-ylamine (6). To a 50 mL round-bottomed flask equipped with stirrer and reflux condenser was added: compound **3b** (150 mg, 0.25 mmol), iron powder (49 mg, 0.87 mmol), glacial acetic acid (0.104 mL, 1.74 mmol), and absolute ethanol (3 mL). The mixture was stirred and refluxed for 2 h under argon and was then added to water (25 mL). The water layer was extracted with chloroform (4×25 mL). The combined organic portions were washed with brine, dried (MgSO₄), filtered, and concentrated in vacuo to give **6** (112 mg, 0.20 mmol, 80%). ¹H NMR (300 MHz, CDCl₃) δ 1.1 (d, 18 H, *J*=6.9 Hz), 1.19 (d, 6H, *J*=6.9 Hz), 1.25 (m, 3H), 2.19 (s, 6H), 3.17 (s, 3H), 3.35 (heptet, 1H, *J*=6.9 Hz), 3.90 (s, 2H), 4.53 (s, 2H), 6.58 (s, 2H), 6.61 (s, 1H), 6.74 (d, 2H, *J*=8.4 Hz), 6.81 (s, 1H), 7.15 (d, 2H, *J*=8.4 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 153.9, 149.5, 145.2, 142.0, 138.1, 137.9, 136.3, 134.5, 130.3, 129.9, 129.7, 127.5, 124.3, 119.4, 114.9, 99.2, 76.4, 57.3, 33.9, 26.4, 23.7, 20.4, 18.0, 12.7.

5'-(4-*tert*-Butoxycarbonylmethoxy-2,6-dimethyl-benzyl)-3'-isopropyl-2'-methoxymethoxy-biphenyl-4-ylaminol]-acetic acid *tert*-butyl ester (7). Compound **6** (85 mg, 0.15 mmol) and Bu₄NF (0.190 mL, 1.0 M in THF) were combined in a round bottom flask. Deprotection was determined to be nearly instantaneous by TLC. The reaction mixture was diluted with ethyl acetate (25 mL) and washed with water (2×25 mL) and brine (30 mL), dried, and concentrated. The crude product was purified by flash column chromatography (80:20 hexane/ethyl acetate) to yield 52 mg, (0.12 mmol, 80%) of 4-(4'-Amino-5-isopropyl-6-methoxymethoxy-biphenyl-3-ylmethyl)-3,5-dimethyl-phenol. To the above phenol (40 mg, 0.092 mmol) and cesium carbonate (150 mg, 0.46 mmol) in 3 mL of DMF was added *tert*-butylchloroacetate (27.86 mg, 0.185 mmol). The reaction

mixture was stirred for 30 min at rt, poured into 15 mL of cold 1 N HCl, and extracted with ethyl acetate (3×10 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 50 mg of crude, which was purified using flash column chromatography (silica gel, 90:20 hexane/ethyl acetate) to yield **7** (45 mg, 0.075 mmol 80%). ¹H NMR (300 MHz, CDCl₃) δ 1.17 (d, 6H, *J*=6.9 Hz), 1.41 (s, 9H), 1.48 (s, 9H), 2.22 (s, 6H), 3.38 (s, 3H), 3.57 (heptet, 1H, *J*=6.9 Hz), 3.86 (s, 2H), 3.93 (s, 2H), 4.49 (s, 2H), 4.54 (s, 2H), 6.60 (s, 2H), 6.66 (d, 2H, *J*=8.7 Hz), 6.70 (s, 1H), 6.85 (s, 1H), 7.30 (d, 2H, *J*=8.7 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 159.3, 156.2, 142.4, 138.5, 136.7, 135.5, 135.3, 128.2, 126.1, 125.5, 125.0, 122.4, 112.8, 112.3, 101.3, 76.2, 73.2, 72.9, 55.5, 50.2, 28.9, 29.0, 24.7, 22.4, 15.3.

{4-[4'-(Carboxymethyl-amino)-6-hydroxy-5-isopropyl-biphenyl-3-ylmethyl]-3,5-dimethyl-phenoxy}-acetic acid (GC-15). To the ester **7** (40 mg, 0.06 mmol) in 2 mL of a 50% (v/v) mixture of *i*-PrOH and THF was added 0.2 mL of 1 N HCl. The reaction mixture was stirred for 2 h at rt, diluted with 3 mL of water and extracted with ethyl acetate (2×15 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 30 mg of the corresponding *O*-methoxymethyl deprotected phenol, which was used directly in the following step. To the above phenol (25 mg, 0.04 mmol) in 2 mL of methanol was added 1.3 mL of 1 N NaOH. The reaction mixture was stirred for 1 h at rt, acidified with 1.5 mL of 2 N HCl, and extracted with ethyl acetate (2×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to give **GC-15** (15 mg, 0.03 mmol, 75%). ¹H NMR (300 MHz, CDCl₃) δ 1.17 (d, 6H, *J*=6.9 Hz), 2.22 (s, 6H), 3.44 (heptet, 1H, *J*=6.9 Hz), 3.92 (s, 2H), 3.98 (s, 2H), 4.60 (s, 2H), 6.65 (s, 2H), 6.68 (s, 1H), 6.84 (d, 2H, *J*=8.4 Hz), 6.90 (s, 1H), 7.31 (d, 2H, *J*=8.4 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 159.3, 151.5, 142.4, 138.5, 136.9, 136.7, 135.8, 128.2, 126.5, 125.9, 125.0, 124.0, 112.8, 112.3, 77.8, 57.1, 28.9, 24.7, 22.1, 15.3. HR-MS calcd for C₂₈H₃₁NO₆: 477.2151. Found: 477.2142.

1-{5'-[2,6-Dimethyl-4-(triisopropyl-silanyloxy)-benzyl]-3'-isopropyl-2'-methoxymethoxy-biphenyl-4-yl}-3-phenylurea (8). To the amine **6** (60 mg, 0.105 mmol) and pyridine (2.65 mg, 0.03 mmol) in 2 mL of DMF was added phenyl isocyanate (14.5 mg, 0.105 mmol). The reaction mixture was stirred for 3 h at rt, poured into 5 mL of water, and extracted with ether (3×10 mL). The combined organic portions were washed with brine (20 mL), dried (MgSO₄), and evaporated to yield 70 mg of crude, which was purified using flash column chromatography (silica gel, 90:20 hexane/ethyl acetate) to yield **8** (55 mg, 0.079 mmol, 75%). ¹H NMR (300 MHz, CDCl₃) δ 1.10 (d, 18 H, *J*=6.9 Hz), 1.17 (d, 6H, *J*=6.9 Hz), 1.25 (m, 3H), 2.18 (s, 6H), 3.26 (s, 3H), 3.37 (heptet, 1H, *J*=6.9 Hz), 3.94 (s, 2H), 4.51 (s, 2H), 6.6 (s, 2H), 6.74 (s, 1H), 6.8 (s, 1H), 7.00 (m, 1H), 7.3–7.5 (m, 8H); ¹³C NMR (300 MHz, CDCl₃) δ 156.2, 152.6, 152.2, 138.4, 138.2, 137.3, 137.1, 135.5, 135.3, 128.7, 127.6, 126.1, 125.5, 124.1, 122.4, 120.9, 120.4, 118.3, 101.3, 50.2, 28.9, 24.7, 22.4, 15.3, 14.8, 2.2.

{4-[6-Hydroxy-5-isopropyl-4'-(3-phenyl-ureido)-biphenyl-3-ylmethyl]-3,5-dimethyl-phenoxy}-acetic acid (GC-16). The above *N,N*-diphenylurea analogue **8** (50 mg, 0.072 mmol) was converted by the procedure described in the synthesis of **GC-14**, starting from compound **3b**, to give **GC-16** (24 mg, 0.045 mmol, 63%). ¹H NMR (300 MHz, CDCl₃) δ 1.18 (d, 6H, *J*=6.9 Hz), 2.21 (s, 6H), 3.30 (heptet, 1H, *J*=6.9 Hz), 3.92 (s, 2H), 4.36 (s, 2H), 6.56 (s, 1H), 6.65 (s, 2H), 6.85 (s, 1H), 7.01 (m, 1H), 7.27–7.32 (m, 4H), 7.41–7.44 (m, 4H); ¹³C NMR (300 MHz, CDCl₃) δ 159.3, 152.2, 151.5, 138.5, 138.2, 137.1, 136.7, 136.9, 135.8, 128.7, 127.6, 126.5, 125.5, 124.0, 124.1, 120.9, 120.4, 112.3, 77.8, 28.9, 24.7, 22.1, 15.3. HR-MS calcd for C₃₃H₃₄N₂O₅: 538.2468. Found: 538.2488.

But-2-ynyl-{5'-[2,6-dimethyl-4-(trisopropyl-silanyloxy)-benzyl]-3'-isopropyl-2'-methoxymethoxy-biphenyl-4-yl}-amine (9). To the amine **6** (70 mg, 0.12 mmol) and cesium carbonate (mg, 0.3 mmol) in 3 mL of DMF was added 1-bromo-2-butyne (0.013 mL, 0.15 mmol). The reaction mixture was stirred for 1 h at rt, poured into 10 mL of cold 1 N HCl, and extracted with ethyl acetate (3×10 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 80 mg of crude, which was purified using flash column chromatography (silica gel, 2:1 hexane/ethyl acetate) to yield **9** (55 mg, 0.09 mmol, 75%). ¹H NMR (300 MHz, CDCl₃) δ 1.12 (d, 18H, *J*=6.9 Hz), 1.18 (d, 6H, *J*=6.9 Hz), 1.25 (m, 3H), 1.81 (s, 3H), 2.18 (s, 6H), 3.27 (s, 3H), 3.42 (heptet, 1H, *J*=6.9 Hz), 3.88 (s, 2H), 3.93 (s, 2H), 4.53 (s, 2H), 6.65 (d, 2H, *J*=4.8 Hz), 6.74 (s, 1H), 6.81 (s, 1H), 7.30 (d, 2H, *J*=4.8 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 156.2, 152.6, 142.4, 138.4, 137.3, 135.5, 135.3, 128.2, 126.1, 125.5, 125.0, 122.4, 118.3, 112.8, 101.3, 76.8, 50.2, 38.8, 28.9, 24.7, 22.4, 15.3, 14.8, 2.2, 1.2.

[4-(4'-But-2-ynylamino-6-hydroxy-5-isopropyl-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid (GC-17). The above amine (50 mg, 0.08 mmol) was converted by the procedure described in the synthesis of **GC-14**, starting from compound **3b**, to give **GC-17** (25 mg, 0.05 mmol, 65%). ¹H NMR (300 MHz, CDCl₃) δ 1.20 (d, 6H, *J*=6.9 Hz), 1.81 (s, 3H), 2.24 (s, 6H), 3.27 (heptet, 1H, *J*=6.9 Hz), 3.89 (s, 2H), 3.92 (s, 2H), 4.63 (s, 2H), 6.55 (s, 1H), 6.62 (s, 2H), 6.72 (d, 2H, *J*=4.8 Hz), 6.87 (s, 1H), 7.20 (d, 2H, *J*=4.8 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 159.3, 151.5, 142.4, 138.5, 136.9, 136.7, 135.8, 128.2, 126.5, 125.9, 125.0, 124.0, 112.8, 112.3, 77.8, 76.8, 38.8, 28.9, 24.7, 22.1, 15.3, 1.2. HR-MS calcd for C₃₀H₃₃NO₄: 471.2410. Found: 471.2421.

[4-(4'-Amino-5-isopropyl-6-methoxymethoxy-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid ethyl ester (10). To a 50 mL round-bottomed flask equipped with stirrer and reflux condenser was added: compound **5b** (75 mg, 0.14 mmol), iron powder (27.4 mg, 0.49 mmol), glacial acetic acid (1.0 mmol), and 5 mL of absolute ethanol. The mixture was stirred and refluxed for 2 h under argon and was then added to water (25 mL). The water layer was extracted with chloroform (4×25 mL). The combined organic portions were washed with brine, dried (MgSO₄), filtered, and concentrated in vacuo to give **10** (55 mg, 0.11 mmol, 78%). ¹H NMR (300 MHz,

CDCl₃) δ 1.18 (d, 6H, *J*=6.9 Hz), 1.27 (t, 3H, *J*=6.8 Hz), 2.23 (s, 6H), 3.28 (s, 3H), 3.40 (heptet, 1H, *J*=6.9 Hz), 3.94 (s, 2H), 4.25 (q, 2H, *J*=6.8 Hz), 4.52 (s, 2H), 4.59 (s, 2H), 6.55 (s, 1H), 6.62 (s, 2H), 6.70 (d, 2H, *J*=8.4 Hz), 6.85 (s, 1H), 7.21 (d, 2H, *J*=8.4 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 159.3, 156.2, 145.6, 138.5, 136.7, 135.5, 135.3, 128.2, 126.6, 126.1, 125.5, 122.4, 115.6, 112.3, 101.3, 75.6, 59.5, 50.2, 28.9, 24.7, 22.4, 15.3.

[4-(4'-Amino-6-hydroxy-5-isopropyl-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid (GC-18). To the ester **10** (50 mg, 0.1 mmol) in 4 mL of a 50% (v/v) mixture of *i*-PrOH and THF was added 0.2 mL of 1 N HCl. The reaction mixture was stirred for 2 h at rt, diluted with 5 mL of water and extracted with ethyl acetate (2×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 45 mg of the corresponding *O*-methoxymethyl deprotected phenol, which was used directly in the following step. To the above phenol (40 mg, 0.09 mmol) in 4 mL of methanol was added 2.6 mL of 1 N NaOH. The reaction mixture was stirred for 1 h at rt, acidified with 3 mL of 2 N HCl, and extracted with ethyl acetate (2×25 mL). The combined organic portions were dried (MgSO₄) and evaporated to give **GC-18** (31.0 mg, 0.072 mmol, 72%). ¹H NMR (300 MHz, CDCl₃) δ 1.18 (d, 6H, *J*=6.9 Hz), 2.23 (s, 6H), 3.40 (heptet, 1H, *J*=6.9 Hz), 3.94 (s, 2H), 4.52 (s, 2H), 6.55 (s, 1H), 6.62 (s, 2H), 6.70 (d, 2H, *J*=8.4 Hz), 6.85 (s, 1H), 7.21 (d, 2H, *J*=8.4 Hz); ¹³C NMR (300 MHz, CDCl₃) δ 159.3, 151.5, 145.6, 138.5, 136.9, 136.7, 135.8, 128.2, 126.6, 126.3, 125.9, 124.0, 115.6, 112.3, 77.8, 28.9, 24.7, 22.1, 15.3. HR-MS calcd for C₂₆H₂₉NO₄: 419.2132. Found: 419.2146.

***N*-{5'-[2,6-Dimethyl-4-(triisopropyl-silanyloxy)-benzyl]-3'-isopropyl-2'-methoxy methoxy-biphenyl-4-yl}-*N*-(2,2,5,7,8-pentamethyl-chroman-6-yl)-guanidine (11).** Compound **6** (260 mg, 0.46 mmol) and Pmc-*S*-methylisothiurea (214 mg, 0.60 mmol) were dissolved in anhydrous THF (20 mL). TEA (0.13 mL, 0.93 mmol) and Hg(ClO₄)₂ (200 mg, 0.51 mmol) were added and the mixture was refluxed overnight. An additional 100 mg (0.7 equiv) of Pmc-*S*-methylisothiurea was added and refluxing continued for another 4 h. The mixture was concentrated in vacuo and the remaining residue was dissolved in ethyl acetate (75 mL), filtered through Celite, which was washed with ethyl acetate (3×50 mL). The combined filtrate was washed with H₂O, satd NaHCO₃, and brine, dried with MgSO₄, filtered, and concentrated in vacuo to yield a yellow foam. The foam was chromatographed on silica gel (3:1 to 2:1 gradient hexane/ethyl acetate) to yield the desired product (206 mg, 51%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 1.1 (d, 18H, *J*=6.9 Hz), 1.21 (d, 6H, *J*=6.9 Hz), 1.25 (m, 3H), 1.31 (s, 6H), 1.82 (t, 2H, *J*=6.8 Hz), 2.13 (s, 3H), 2.18 (s, 6H), 2.62 (s, 3H), 2.64 (s, 3H), 2.65 (t, 2H, *J*=6.8 Hz), 3.23 (s, 3H), 3.39 (heptet, 1H, *J*=6.9 Hz), 3.95 (s, 2H), 4.51 (s, 2H), 6.60 (s, 2H), 6.65 (s, 1H), 6.94 (s, 1H), 7.21 (d, 2H, *J*=8.4 Hz), 7.51 (d, 2H, *J*=8.4 Hz); ¹³C NMR (400 MHz, CDCl₃) δ 154.4, 153.9, 149.6, 142.4, 138.7, 138.0, 136.5, 135.7, 135.2, 134.1, 133.4, 132.8, 130.9, 129.4, 127.3, 125.7, 124.8, 124.2, 119.5, 118.0, 99.56, 73.7, 57.2, 33.9, 32.8, 26.7, 26.4, 23.7, 21.4, 20.4, 18.5, 17.9, 17.4, 12.6, 12.1.

(4-{5-Isopropyl-6-methoxymethoxy-4'-[N-(2,2,5,7,8-pentamethyl-chroman-6-yl)-guanidino]-biphenyl-3-ylmethyl}-3,5-dimethyl-phenoxy)-acetic acid tert-butyl ester (12). Compound **11** (195 mg, 0.22 mmol) and Bu₄NF (0.28 mL, 1.0 M in THF) were combined in a round bottom flask. The reaction was allowed to stir at rt for 10 min. It was then diluted with ether (25 mL) and washed with water (2×25 mL) and brine (30 mL), dried over MgSO₄, and concentrated to yield orange foam. The crude product was purified by flash column chromatography (2:1 hexane/ethyl acetate) to yield 153 mg (96%) of the desired phenol product, which was used directly in the following step. To the above phenol (145.0 mg, 0.20 mmol) and cesium carbonate (335.0 mg, 1.00 mmol) in 5 mL DMF, was added *tert*-butylchloroacetate (0.036 mL, 0.25 mmol). The reaction mixture was stirred for 30 min at rt, poured into 10 mL of cold 1 N HCl, and extracted with ethyl acetate (3×10 mL). The combined organic portions were dried (MgSO₄) and evaporated to yield 100 mg of crude, which was purified using flash column chromatography (silica gel, 4:1 hexane/ethyl acetate) to yield **12** (50.0 mg, 0.06 mmol, 30%). ¹H NMR (400 MHz, CDCl₃) δ 1.19 (d, 6H, *J*=6.9 Hz), 1.31 (s, 6H), 1.48 (s, 9H), 1.81 (t, 2H, *J*=6.8 Hz), 2.12 (s, 3H), 2.21 (s, 6H), 2.60 (s, 3H), 2.62 (s, 3H), 2.65 (t, 2H, *J*=6.8 Hz), 3.22 (s, 3H), 3.39 (heptet, 1H, *J*=6.9 Hz), 3.95 (s, 2H), 4.48 (s, 2H), 4.50 (s, 2H), 6.61 (s, 2H), 6.64 (s, 1H), 6.95 (s, 1H), 7.25 (d, 2H, *J*=8.4 Hz), 7.47 (d, 2H, *J*=8.4 Hz); ¹³C NMR (400 MHz, CDCl₃) δ 154.3, 153.9, 149.5, 142.3, 138.4, 137.6, 136.5, 135.7, 135.1, 134.8, 133.7, 132.7, 130.4, 128.7, 127.1, 125.7, 124.2, 123.7, 118.0, 114.9, 99.4, 75.6, 73.7, 59.5, 57.2, 33.9, 32.7, 26.7, 26.4, 23.7, 21.4, 20.3, 18.5, 17.5, 14.1, 13.6, 12.1.

[4-(4'-Guanidino-6-hydroxy-5-isopropyl-biphenyl-3-ylmethyl)-3,5-dimethyl-phenoxy]-acetic acid (GC-23). To the ester **12** (32.0 mg, 0.04 mmol) dissolved in CH₂Cl₂ (3 mL) was added TFA (3 mL). The reaction was stirred at rt for 1 h. The reaction mixture was then diluted with ethyl acetate (25 mL) and washed with satd NaHCO₃ (5×15 mL), water, and brine. The combined organic portions were dried (MgSO₄) and evaporated. The crude product was purified by preparative TLC (4:1:1 ethyl acetate/hexane/MeOH) to yield the desired product **GC-23** (20.0 mg, 0.03 mmol, 75%). ¹H NMR (400 MHz, CDCl₃) δ 1.24 (d, 6H, *J*=6.9 Hz), 2.20 (s, 6H), 2.60 (s, 3H), 3.22 (s, 3H), 3.33 (heptet, 1H, *J*=6.9 Hz), 3.93 (s, 2H), 4.40 (s, 2H), 6.44 (s, 1H), 6.62 (s, 2H), 7.01 (s, 1H), 7.22 (d, 2H, *J*=8.0 Hz), 7.44 (d, 2H, *J*=8.0 Hz); ¹³C NMR (400 MHz, CDCl₃) δ 157.3, 151.5, 145.6, 139.8, 138.6, 137.1, 133.7, 131.7, 130.4, 128.9, 126.1, 124.2, 114.8, 99.4, 77.6, 28.9, 24.7, 22.1, 15.6. HR-MS calcd for C₂₇H₃₁N₃O₄: 461.2315. Found: 461.2333.

Acknowledgements

This work was supported by grants from the National Institutes of Health (DK 52798, T.S.S.; DK 41842, J.D.B.). J.D.B. has proprietary interests in, and serves as a consultant and deputy director to Karo Bio AB, which has commercial interests in this area of research.

References and Notes

- Chiellini, G.; Apriletti, J. W.; Yoshihara, H. A.; Baxter, J. D.; Ribeiro, R. C. J.; Scanlan, T. S. *Chem. Biol.* **1998**, *5*, 299.
- Chiellini, G.; Nguyen, N. H.; Yoshihara, H. A. I.; Scanlan, T. S. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 2607.
- Greenspan, F. S. In *Basic & Clinical Endocrinology*, 5th ed.; Greenspan, F. S., Strewler, G. J., Eds.; Appleton & Lange: Stamford, 1997.
- Oppenheimer, J. H.; Apriletti, J. W.; Samuels, H. H. *Molecular Basis Of Thyroid Hormone Action*; Academic: New York, 1983.
- Utiger, L. E. B.; Utiger, R. D. *The Thyroid: A Fundamental and Clinical Text*; Lippincott: Philadelphia, 1991.
- Evans, R. M. *Science* **1988**, *240*, 889.
- Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans, R. M. *Cell* **1995**, *83*, 835.
- Katzenellenbogen, J. A.; Katzenellenbogen, B. S. *Chem. Biol.* **1996**, *3*, 529.
- Lazar, M. A. *Endocrine Rev.* **1993**, *14*, 184.
- Darimont, B. D.; Wagner, R. L.; Apriletti, J. W.; Stallcup, M. R.; Kushner, P. J.; Baxter, J. D.; Fletterick, R. J.; Yamamoto, K. R. *Genes Dev.* **1998**, *12*, 3343.
- Wagner, R. L.; Apriletti, J. W.; McGrath, M. E.; West, B. L.; Baxter, J. D.; Fletterick, R. J. *Nature* **1995**, *378*, 690.
- Wagner, R. L.; Huber, R.; Shiau, A. K.; Kelly, A.; Cunha Lima, S. T.; Scanlan, T. S.; Apriletti, J. W.; Baxter, J. D.; West, B. L.; Fletterick, R. J. *Mol. Endocrinol.* **2001**, *15*, 398.
- Hodin, R. A.; Lazar, M. A.; Chin, W. W. *J. Clin. Invest.* **1990**, *85*, 101.
- Mitsushashi, T. G.; Tennyson, G. E.; Nikodem, U. M. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85*, 5804.
- Mitsushashi, T. G.; Nikodem, U. M. *J. Biol. Chem.* **1989**, *264*, 8900.
- Hodin, R. A.; Lazar, M. A.; Wintman, B. I.; Darling, D. S.; Koenig, R. J.; Larsen, P. R.; Moor, D. D.; Chin, W. W. *Science* **1989**, *244*, 76.
- Baxter, J. D.; Dillmann, W. H.; West, B. L.; Huber, R.; Furlow, J. D.; Fletterick, R. J.; Webb, P.; Apriletti, J. W.; Scanlan, T. S. *J. Steroid Biochem. Mol. Biol.* **2001**, *76*, 31.
- Jorgensen, E. C. In *Hormonal Proteins and Peptides*; Choh, H., L., Ed.; Academic: New York, 1978; Vol. VI.
- Underwood, A. H.; Emmett, J. C.; Ellis, D.; Flynn, S. B.; Leeson, P. D.; Benson, G. M.; Novelli, R.; Pearce, N. J.; Shah, V. P. *Nature* **1986**, *324*, 425.
- Taylor, A. H.; Stephan, Z. F.; Steele, R. E.; Wong, N. C. W. *Mol. Pharmacol.* **1997**, *52*, 542.
- Weatherman, R. V.; Fletterick, R. J.; Scanlan, T. S. *Annu. Rev. Biochem.* **1999**, *68*, 559.
- Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J. A.; Carlquist, M. *Nature* **1997**, *389*, 753.
- Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. *Cell* **1998**, *95*, 927.
- Caron, S.; Hawkins, J. M. *J. Org. Chem.* **1998**, *63*, 2054.
- Kent, D. R.; Cody, W. L.; Doherty, A. M. *Tetrahedron Lett.* **1996**, *37*, 8711.
- Apriletti, J. W.; Baxter, J. D.; Lau, K. H.; West, B. L. *Protein Express. Purif.* **1995**, *6*, 363.
- Swillens, S. *Mol. Pharmacol.* **1995**, *47*, 1197.
- Ribeiro, R. C. J.; Cavalieri, R. R.; Lomri, N.; Rahmaoui, C. M.; Baxter, J. D.; Scharschmidt, B. F. *J. Biol. Chem.* **1996**, *271*, 17147.
- Leitman, D. C.; Ribeiro, R. C.; Mackow, E. R.; Baxter, J. D.; West, B. L. *J. Biol. Chem.* **1991**, *266*, 9343.
- Brasier, A. R.; Tate, J. E.; Habener, J. F. *Bio Techniques* **1989**, *7*, 1116.